Meridian Bioscience Europe Announces Agreement to Distribute Test For GI Disease

Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) announced today that Meridian Bioscience Europe srl, Milan, Italy has signed an agreement with BÜHLMANN Laboratories AG, Schönenbuch, Switzerland for distribution in Italy of an innovative test for inflammatory conditions of the intestine, Quantum Blue^® Calprotectin. The test which detects calprotectin, a GI inflammatory marker, is a fundamental tool in differentiating between Inflammatory Bowel Disease (IBD) and Irritable Bowel Syndrome (IBS). Patients suffering from IBS do not have increased faecal calprotectin values. Faecal calprotectin concentrations, as measured by the BÜHLMANN Calprotectin assay, are significantly elevated in patients with IBD and correlate well with endoscopic an histological assessment of disease activity. Over two million patients in Europe suffer from IBD, and it is estimated that IBS affects more than 30 million Europeans. This novel and simple test will avoid unnecessary colon endoscopies for Ulcerative Colitis or Crohn's disease and will minimize discomfort while offering substantial savings for patients and health systems.

Antonio Interno, President of Meridian Bioscience Europe, commented: "The BÜHLMANN Calprotectin test fits very well in Meridian's gastroenteric product range providing another key technology for our lab customers. Preliminary customer interest and sales indicate that the BÜHLMANN Calprotectin test will contribute to FY2010 revenues in Italy. We are also discussing the extension of the distribution agreement to the French market."

Forward Looking Statements

The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, which may be identified by words such as "estimates", "anticipates", "projects", "plans", "seeks", "may", "will", "expects", "intends", "believes", "should" and similar expressions or the negative versions thereof and which also may be identified by their context. Such statements, whether expressed or implied, are based upon current expectations of the Company and speak only as of the date made. The Company assumes no obligation to publicly update or revise any forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized. These statements are subject to various risks, uncertainties and other factors that could cause actual results to differ materially, including, without limitation, the following: Meridian's continued growth depends, in part, on its ability to introduce into the marketplace enhancements of existing products or new products that incorporate technological advances, meet customer requirements and respond to products developed by Meridian's competition. While Meridian has introduced a number of internally developed products, there can be no assurance that it will be successful in the future in introducing such products on a timely basis. Ongoing consolidations of reference laboratories and formation of multi-hospital alliances may cause adverse changes to pricing and distribution. Recessionary pressures on the economy and the markets in which our customers operate can change expected results, as well as adverse trends in buying patterns from customers. Costs and difficulties in complying with laws and regulations administered by the United States Food and Drug Administration can result in unanticipated expenses and delays and interruptions to the sale of new and existing products. Changes in the relative strength or weakness of the U.S. dollar can also change expected results. One of Meridian's main growth strategies is the acquisition of companies and product lines. There can be no assurance that additional acquisitions will be consummated or that, if consummated, will be successful and the acquired businesses successfully integrated into Meridian's operations. In addition to the factors described in this paragraph, Part I, Item 1A Risk Factors of our Form 10-K contains a list and description of uncertainties, risks and other matters that may affect the Company which are incorporated by reference into this press release.

Meridian is a fully integrated life science company that manufactures, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and related products and offers biopharmaceutical enabling technologies. Utilizing a variety of methods, these products and diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as gastrointestinal, viral and respiratory infections. Meridian’s diagnostic products are used outside of the human body and require little or no special equipment. The Company's products are designed to enhance patient well-being while reducing the total outcome costs of healthcare. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections, serology, parasitology and fungal disease diagnosis. In addition, Meridian is a supplier of rare reagents, specialty biologicals and related technologies used by biopharmaceutical companies engaged in research for new drugs and vaccines. The Company markets its products and technologies to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers and biotech companies in more than 60 countries around the world. The Company’s shares are traded through NASDAQ’s Global Select Market, symbol VIVO. Meridian's website address is www.meridianbioscience.com.